Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Axsome Therapeutics, Inc.

< Previous 1 2 Next >
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.